This inventor holds 1 USPTO granted patent. Top assignee: Clearnote Health, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Samuel Levy: Inventor in Pancreatic Cancer Diagnostics
Introduction
Samuel Levy is an inventor associated with San Mateo, California, and Clearnote Health, Inc. His work includes a patent application concerning the use of cell-free DNA hydroxymethylation profiles to evaluate pancreatic lesions.
Latest Patents
Levy is associated with 1 patent: “Cell-free DNA hydroxymethylation profiles in the evaluation of pancreatic lesions.” The invention describes methods for identifying patients with pancreatic cancer or elevated risk, monitoring patients with pancreatic lesions, assessing treatment effectiveness, and selecting therapies. It uses hydroxymethylation biomarkers, potentially alongside clinical parameters, other biomarkers, and patient-specific risk factors, to help evaluate pancreatic cancer. The disclosure also describes kits and related methods of use.
Career Highlights
The available information connects Levy’s patent work with Clearnote Health, Inc. The disclosed approach focuses on molecular biomarkers that may support the evaluation and management of pancreatic lesions.
Collaborations
The listed coworkers associated with Levy are Patrick A. Arensdorf and Chin-Jen Ku. Their inclusion indicates a professional connection in the provided information, but specific roles or contributions are not stated.
Conclusion
Samuel Levy’s listed invention applies cell-free DNA hydroxymethylation profiles to pancreatic cancer evaluation, reflecting a diagnostic approach centered on biomarkers and patient-specific information.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile